Kanvas key facts
- Developer of a healthcare imaging technology designed to bring microbiome drug discovery into focus and microbial detection.
- Kanvas’s last known valuation is $50.0M.
- It has raised $24.5M; the latest was Seed Round ($12.5M) in Jul 2024.
- Notable investors include Mana Ventures, DCVC, FemHealth Ventures, Ki Tua Fund, Germin8 Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch Kanvas: the Monday email on marks, rounds and moves
Kanvas funding rounds
No funding rounds for Kanvas are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Kanvas valuation
Kanvas's last known valuation is $50 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Kanvas investors
10 investors are on record for Kanvas, including Mana Ventures, DCVC, FemHealth Ventures and Ki Tua Fund.
About Kanvas
Developer of a healthcare imaging technology designed to bring microbiome drug discovery into focus and microbial detection. The company develops a multiplexed imaging technology for microbial detection by illuminating microbial life with the help of cells, providing researchers with tools for research, and creating cures for infectious diseases.
- Sector
- Healthcare
- HQ
- Monmouth Junction, NJ, United States
- Founded
- 2020
- Employees
- 34
- Website
- kanvasbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Kanvas’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.